Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891670 | 0.84 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5251164 | 0.82 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11697939 | 0.82 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8413718 | 0.80 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL58465 | 0.80 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL140991 | 0.77 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10957944 | 0.77 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10787067 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27567153 | 0.74 | EPHX2 (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL919012 | 0.74 | MEN1 (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115443293-A | Composition for encapsulating organic light emitting element and organic light emitting display device comprising same | 索路思高新材料有限公司 | 2022-12-06 | — | — | CN | claimed |
| EP-3849992-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-07-21 | — | — | EP | claimed |
| WO-2020051686-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO. LTD. (CN) | 2020-03-19 | — | — | WO | claimed |
| US-8901155-B2 | Method for treating a TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | claimed |
| EP-2666767-A1 | Therapeutic agent for TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-27 | — | — | EP | claimed |
| EP-2210878-B1 | THERAPEUTIC AGENT FOR OVERACTIVE BLADDER | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-07-31 | — | — | EP | claimed |
| CN-101827816-B | Therapeutic agent for TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO LTD | 2013-05-08 | — | — | CN | claimed |
| US-20130090359-A1 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-11 | — | — | US | claimed |
| US-20100261911-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | claimed |
| CN-101827816-A | Therapeutic agent for TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO LTD | 2010-09-08 | — | — | CN | claimed |
| EP-0882023-B1 | HISTAMINE H 3 RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2003-06-04 | — | — | EP | claimed |
| EP-0812205-B1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 2001-03-14 | — | — | EP | claimed |
| EP-1056733-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-12-06 | — | — | EP | claimed |
| US-6080871-A | ANTIHISTAMINES | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-06-27 | — | — | US | claimed |
| WO-1999042458-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-08-26 | — | — | WO | claimed |
| CN-1215392-A | Histamine H3 receptor ligands | BLACK JAMES FOUNDATION (GB) | 1999-04-28 | — | — | CN | claimed |
| EP-0882023-A1 | HISTAMINE H 3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1997029092-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-08-14 | — | — | WO | claimed |
| EP-0531382-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-03-17 | — | — | EP | claimed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261911-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | TRPV1, TRPA1, TRPV3 | GRIN2D 1943/4885GRIN3B 603/4885GRIN1 378/4885 |
| US-20130090359-A1 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE | TRPV1, TRPV3, TRPV2 | GRIN2D 752/4885GRIN3B 508/4885GRIN1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.